American Heart Journal
Volume 155, Issue 6 , Pages 1075-1080, June 2008

Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stents☆☆☆

  • Mehdi H. Shishehbor, DO, MPH

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Reza Amini, MD

      Affiliations

    • Internal Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Russell E. Raymond, DO

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Anthony A. Bavry, MD, MPH

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Sorin J. Brener, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Samir R. Kapadia, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Patrick L. Whitlow, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Stephen G. Ellis, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • ,
  • Deepak L. Bhatt, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
    • Corresponding Author InformationReprint requests: Deepak L. Bhatt, MD, FACC, FSCAI, FESC, Department of Cardiovascular Medicine, Desk F-25, 9500 Euclid Ave, Cleveland, OH 44195.

Received 1 October 2007; accepted 22 January 2008. published online 06 March 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This is supported in part by the National Institutes of Health, National Institute of Child Health and Human Development, Multidisciplinary Clinical Research Career Development Programs grant K12 HD049091 and the National Institutes of Health Loan Repayment Program (Dr Shishehbor).

☆☆ MHS, RA, AAB, SJB, SRK have no conflict of interest to report. RER serves on the Boston Scientific speaker's bureau. DLB discloses the following relationships: research grants (directly to the institution)—Bristol Myers Squibb, Eisai, Ethicon, Heartscape, Sanofi Aventis, and The Medicines Company; honoraria (donated to nonprofits for >2 years)—Astra Zeneca, Bristol Myers Squibb, Centocor, Daiichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Millennium, Paringenix, PDL, Sanofi Aventis, Schering Plough, The Medicines Company, and tns Healthcare; speaker's bureau (>2 years ago)—Bristol Myers Squibb, Sanofi Aventis, and The Medicines Company; consultant/advisory board (donated to nonprofits for >2 years)—Astellas, Astra Zeneca, Bristol Myers Squibb, Cardax, Centocor, Cogentus, Daiichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Johnson&Johnson, McNeil, Medtronic, Millennium, Molecular Insights, Otsuka, Paringenix, PDL, Philips, Portola, Sanofi Aventis, Schering Plough, Scios, Takeda, The Medicines Company, tns Healthcare, and Vertex; expert testimony regarding clopidogrel (>2 years ago; the compensation was donated to a nonprofit organization); Cleveland Clinic Coordinating Center currently receives or has received research funding from Abraxis, Alexion Pharma, AstraZeneca, Atherogenics, Aventis, Biosense Webster, Biosite, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardionet, Centocor, Converge Medical Inc, Cordis, Dr Reddy's, Edwards Lifesciences, Esperion, GE Medical, Genentech, Gilford, GSK, Guidant, J&J, Kensey-Nash, Lilly, Medtronic, Merck, Mytogen, Novartis, Novo Nordisk, Orphan Therapeutics, P&G Pharma, Pfizer, Roche, Sankyo, Sanofi-Aventis, Schering Plough, Scios, St Jude Medical, Takeda, TMC, VasoGenix, and Viacor. SGE serves on the advisory board of Cordis and Boston Scientific Inc. PLW serves as a consultant and/or on the advisory board of ICON Interventional Systems and Medlogics.

PII: S0002-8703(08)00063-X

doi:10.1016/j.ahj.2008.01.017

American Heart Journal
Volume 155, Issue 6 , Pages 1075-1080, June 2008

Article Tools